Narrative Update on Rossari Biotech: Analyst Price Target Revision
Analysts have revised Rossari Biotech’s fair value estimate downward from ₹826.67 to ₹795.75, citing slightly lower expectations for revenue growth and profit margins.
What's in the News
- The company commissioned an additional 20,000 MTPA capacity at its Dahej facility, bringing total installed capacity to 1,52,500 MTPA (Key Developments).
- Commissioned 15,000 MTPA ethoxylation capacity at Unitop, which marks Phase 1 of a 30,000 MTPA expansion plan. The current Unitop capacity is now 51,000 MTPA (Key Developments).
- The second phase of the Unitop ethoxylation expansion is expected to be commissioned by the third quarter of fiscal year 2026 (Key Developments).
- The Board approved an investment of up to USD 8 million in Rossari International Limited Company, a wholly owned subsidiary in Saudi Arabia, to support global expansion plans (Key Developments).
- A Board meeting is scheduled for October 15, 2025, to approve unaudited financial results for the quarter and half year ended September 30, 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target: lowered from ₹826.67 to ₹795.75. This reflects a moderate decrease in fair value estimates.
- Discount Rate: reduced slightly from 13.62% to 13.59%.
- Revenue Growth: forecasted growth decreased from 16.63% to 15.30% per year.
- Net Profit Margin: revised down from 7.49% to 7.40%.
- Future P/E: modestly reduced from 26.29x to 25.45x.
Have other thoughts on Rossari Biotech?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.